160 related items for PubMed ID: 28343657
1. Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease.
Nagakura A, Morikawa Y, Sakakibara H, Miura M.
J Pediatr; 2017 Jun; 185():106-111.e1. PubMed ID: 28343657
[Abstract] [Full Text] [Related]
2. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[Abstract] [Full Text] [Related]
3. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A.
J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
[Abstract] [Full Text] [Related]
4. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
Kobayashi T, Kobayashi T, Morikawa A, Ikeda K, Seki M, Shimoyama S, Ishii Y, Suzuki T, Nakajima K, Sakamoto N, Arakawa H.
J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
[Abstract] [Full Text] [Related]
5. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.
Goto M, Miyagawa N, Kikunaga K, Miura M, Hasegawa Y.
Endocr J; 2015 Aug; 62(2):145-51. PubMed ID: 25342092
[Abstract] [Full Text] [Related]
6. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
Jibiki T, Kato I, Shiohama T, Abe K, Anzai S, Takeda N, Yamaguchi KI, Kanazawa M, Kurosaki T.
Pediatr Int; 2011 Oct; 53(5):729-735. PubMed ID: 21342358
[Abstract] [Full Text] [Related]
7. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
Sakai H, Iwashima S, Sano S, Akiyama N, Nagata E, Harazaki M, Fukuoka T.
Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
[Abstract] [Full Text] [Related]
8. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
9. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
Kobayashi T, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H.
Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
[Abstract] [Full Text] [Related]
10. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Nakagama Y, Inuzuka R, Hayashi T, Shindo T, Hirata Y, Shimizu N, Inatomi J, Yokoyama Y, Namai Y, Oda Y, Takamizawa M, Harita Y, Oka A.
Pediatr Int; 2016 Mar; 58(3):180-184. PubMed ID: 26222760
[Abstract] [Full Text] [Related]
11. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
[Abstract] [Full Text] [Related]
12. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ, Jung JW.
Yonsei Med J; 2014 Sep 06; 55(5):1260-6. PubMed ID: 25048483
[Abstract] [Full Text] [Related]
13. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S, Dong Y, Yin Y, Krucoff MW.
Heart; 2013 Jan 06; 99(2):76-82. PubMed ID: 22869678
[Abstract] [Full Text] [Related]
14. [Methylprednisolone pulse therapy in Kawasaki disease].
Miura M, Matsuoka M, Kohno K, Ohki H, Yoshiba S.
Nihon Rinsho; 2008 Feb 06; 66(2):338-42. PubMed ID: 18265457
[Abstract] [Full Text] [Related]
15. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
Kimura M, Harazaki M, Fukuoka T, Asakura I, Sakai H, Kamimaki T, Ohkawara I, Akiyama N, Tsurui S, Iwashima S, Shimomura M, Morishita H, Meguro T, Seto S.
Pediatr Int; 2017 Apr 06; 59(4):397-403. PubMed ID: 27743415
[Abstract] [Full Text] [Related]
16. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
Arch Dis Child; 2008 Feb 06; 93(2):142-6. PubMed ID: 17962370
[Abstract] [Full Text] [Related]
17. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec 06; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
18. Role of glucocorticoids in Kawasaki disease.
Miura M.
Int J Rheum Dis; 2018 Jan 06; 21(1):70-75. PubMed ID: 29105310
[Abstract] [Full Text] [Related]
19. Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease.
Takeshita S, Kawamura Y, Nakatani K, Tsujimoto H, Tokutomi T.
Clin Pediatr (Phila); 2005 Jun 06; 44(5):423-6. PubMed ID: 15965549
[Abstract] [Full Text] [Related]
20. Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.
Yoshikane Y, Okuma Y, Miyamoto T, Hashimoto J, Fukazawa R, Kato T, Takeda A, Suda K, Matsushita T, Hiroe M, Imanaka-Yoshida K.
Pediatr Rheumatol Online J; 2021 Jun 05; 19(1):82. PubMed ID: 34090475
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
